Myriad keeps racking up companion Dx deals; Labs in India slash price of key TB test;

> Myriad Genetics ($MYGN) has licensed its homologous recombination deficiency cancer test to its fifth partner in the space: oncology biotech Tesaro ($TSO). Story

> Biocept ($BIOC), a California developer of cancer molecular diagnostic tests, has hired a veteran of Life Technologies ($LIFE) and GE Healthcare's ($GE) Clarient as its new vice president of commercial operations. Release

> Minnesota's MGC Diagnostics ($MGCD) will acquire Belgium's Medisoft SA, a privately held maker of cardiorespiratory diagnostic products. Release

> The Alzheimer's Disease and Dementia Initiative at the New York Academy of Sciences and the Alzheimer's Drug Discovery Foundation, along with companies including AstraZeneca ($AZN), Merck ($MRK) and others, have funded an Australian trial that will attempt to validate a protein biomarker test to detect Alzheimer's disease. Story (reg. req.)

> More than 60 private labs in India have slashed the price on a key tuberculosis test in the run-up to World TB day. Story

Editor's Note: A story in last week's FierceDiagnostics mischaracterized Corgenix's financial statement. The company's annual revenue was just over $10 million--not its earnings, as originally reported. 

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.